VTN and Alzheimer disease: A role for complement as a driver of inflammation in the AD brain first emerged in the 1980s, based upon guilt by association; immunohistochemistry in late-stage AD brain demonstrated that the prototypical lesions, amyloid plaques, were richly decorated with complement proteins [40–43].